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Histone deacetylase inhibitors (HDACs) are known to exhibit antiproliferative effects on various carcinoma cells. In this study, the in
vivo efficiency of two HDACs, sodium butyrate and tributyrin, on prostate cancer growth inhibition were investigated. To gain an
insight into the possible underlying pathways, cell culture experiments were performed focusing on the expression of p21, Rb and c-
myc. For in vivo testing, prostate cancer cell lines (PC3 and TSU-Pr1) were seeded on the chorioallantois membrane (CAM) and
implanted in a xenograft model using nude mice. Standard Western blot analysis was performed for protein expression of p21, Rb
and c-myc in HDAC-treated vs untreated prostate cancer cells. Both sodium butyrate and tributyrin had a considerable treatment
effect on microtumours on the chicken egg at already very low concentrations of 0.1mM. Tributyrin-treated tumours showed the
strongest effect with 38% apoptotic nuclei in the prostate cancer cell line PC3. In the mouse model, there was almost no difference
between sodium butyrate and tributyrin. In untreated animals the tumours were almost double the size 4 weeks after implantation.
Tumours of the treatment groups had a significantly lower percentage of Ki-67-positive-stained nuclei. As demonstrated by Western
blot analysis, these effects seem to be independent of p53 status and a pathway via p21–Rb–c-myc is possibly involved. In this study
we have demonstrated a substantial in vivo treatment effect, which can be induced by the application of sodium butyrate or the orally
applicable tributyrin in human prostate cancer. The given results may provide the rationale to apply these drugs in well-controlled
clinical trials in patients being at high risk of recurrence after specific therapy or in patients with locally or distant advanced prostate
cancer.
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Prostate cancer has the highest incidence and is the second leading
cause of cancer deaths among men in the United States (Jemal et al,
2002). With a response rate of about 80%, androgen ablation
induces apoptosis of normal prostate epithelial cells as well as
regression of early-stage prostate cancer. However, progression to
androgen independence occurs over time, so that this treatment
option is not curative (Samson et al, 2002). Conventional
chemotherapy has not sufficiently been proven to be effective
either, especially in androgen-independent prostate cancer, and is
limited by toxicity that is often aggravated by comorbidity of the
elderly prostate cancer patients (Yagoda and Petrylak, 1993).
Promising results of a single agent have so far been reported only
by the usage of Docetaxel (Taxotere) (Picus and Schultz, 1999).
There is a tremendous need to identify substances suitable for the
prevention of progression and as a means for a better cancer
control in advanced prostate cancer cases.
Agents that are active against prostate cancer alter cell growth
and differentiation by modifying the expression of genes or gene
products that regulate cell shape, function, adhesion and commu-
nication. Such compounds are for example butyrates, members of
the group of histone deacetylase inhibitors (HDACs) (Gleave et al,
1998). Butyrates are naturally occurring short-chain fatty acids
leading to differentiation of numerous cell types (Chen and
Breitman, 1994). The potential clinical utility of butyric acid is
mainly limited by a short half-life in vivo as plasma concentrations
decrease within minutes below the concentration needed for effects
in vitro (Miller et al, 1987). To circumvent the problem of fast
metabolism of butyrate monomers, analogues have been tested
(Planchon et al, 1993). Tributyrin is a readily available trimer of
butyric acid and is cleaved intracellular by lipases into three
molecules of butyric acid. It has been shown that tributyrin can
induce differentiation in human myeloid leukaemia cells, murine
erythroleukaemia cells (Chen and Breitman, 1994), MCF-7
mammary carcinoma cells (Heerdt et al, 1999) and HT-29 colon
cancer cells (Schroder et al, 1998). We have previously demon-
strated that butyrates strongly induce in vitro growth inhibition
and apoptosis in different human prostate cancer cell lines (Maier
et al, 2000).
The objective of the present study was to determine whether in
vivo prostate cancer tumour growth and progression are delayed
under treatment with the butyrates sodium-butyrate and tributyr-
in. Testing was performed in vivo on the chorioallantois
membrane (CAM) of fertilised chicken eggs (Kunzi-Rapp et al,
2001). For confirmation, a nude mouse model was explored with a
study design of multiple dosing over 4 weeks. Immunohistochem-
istry for documentation of treatment-associated reduction of
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sproliferation was performed. In addition, cell culture experiments
were carried out to gain a further insight into the pathways
possibly influenced by butyrates. Based on previous reports, the
induction of p21, activation of the Rb protein and expression of c-
myc were evaluated under treatment conditions with the HDACs
(Blagosklonny et al, 1997; Claassen and Hann, 2000; Rashid et al,
2001).
MATERIALS AND METHODS
Cell culture and reagents
The LNCaP, PC3 and Tsu-Pr1 cell lines were obtained from
American Type Culture Collection (Rockwell, MD, USA). All cell
lines were cultured and maintained in 5% CO2 at 371C in RPMI
1640 (Life Technologies, Eggenstein, Germany), supplemented
with 10% heat-inactivated foetal calf serum, 2mML -glutamine,
100Uml
 1 penicillin G and 100Uml
 1 streptomycin (Life
Technologies, Eggenstein, Germany). Sodium butyrate and tribu-
tyrin were obtained from Sigma-Aldrich Chemie GmbH (Deisen-
hofen, Germany). A stock solution of tributyrin was prepared
using 100% ethanol. Sodium butyrate was dissolved in sterile
water.
Growth inhibition in cell culture
For determining cell proliferation, the viable cell numbers were
counted using the Cell Proliferation Kit II (Roche Diagnostics
GmbH, Mannheim, Germany) based on the XTT assay (Roehm
et al, 1991). In brief, cells were grown in microtitre plates to 80%
confluency. Cells were incubated with the given final concentration
of the butyrates for 72h. After incubation, 50ml of XTT labelling
mixture was added to each well. The microtitre plate was incubated
for another 4h before measuring absorbance at 492nm (reference
wavelength 690nm) of the samples using a microtitre plate reader
(SLT spectra, Tecan GmbH, Crailsheim, Germany).
Chorioallantois membrane
Preparation and procedure of grafting Fertilised chicken eggs
were incubated at 37.81C and 60% relative humidity. On day 4 of
incubation, implantation was prepared. Standard microbiology
testing was used to rule out subclinical infections. The procedure
of preparing the CAM was carried out as described previously
(Kunzi-Rapp et al, 2001). Briefly, a part of the CAM was exposed
by peeling a round aperture of 2cm diameter. The resulting
window was covered with a self-adhesive stripe and incubation was
continued. At day 7 of incubation, a silicone ring with a thickness
of 0.5mm and an inner diameter of 6mm was placed onto the
membrane. The cells were seeded into the ring at a concentration
of 5 10
5 cells in 25ml serum-free RPMI 1640. Tumour growth and
viability of the embryo were controlled daily by stereo microscopy.
In vivo apoptosis induction Tumours were established as
described 3 days after the inoculation of tumours on the CAM,
sodium butyrate or tributyrin was administered intravenously
(i.v.) into the CAM vessels using a 0.3 13mm needle in a total
volume of 100ml. The final in vivo concentration was calculated for
a total blood volume of 2cm
3 and varied from 0.1 to 5.0mM for
tributyrin and sodium butyrate. At 48h after application, the
tumour, together with the CAM, was sampled for immunohisto-
chemistry and apoptosis detection.
Quantitative assessment of apoptosis in implanted tumours The
detection of apoptotic cells was performed as described previously
(Maier et al, 2000). Tumours were sampled 5 days after seeding
and embedded in paraffin. Sections of 3mm were mounted on
poly-L-lysine-coated slides. After deparaffinising and rehydration,
slides were washed twice in PBS and treated with 0.1% H2O2 in PBS
for 15min. After repeated washing in dH2O and TdT buffer (30mM
Tris, pH 7.2, 140mM sodium cacodylate, 1mM cobalt chloride),
slides were incubated with TdT–Biotin–dUTP mix (100ml TdT
buffer, 30U TdT, 0.5ml Biotin–dUTP; Boehringer Mannheim,
Indianapolis, IN, USA) for 1h at 371C in a humid chamber. The
reaction was stopped and unspecific binding was blocked by
incubation in 2% BSA for 10min at room temperature. Slides were
incubated with a secondary antibody (ABC Vectastain, Vector
Laboratories, Inc., Burlingame, CA, USA) for 30min in a humid
chamber at room temperature. Slides were washed and stained
with 3-amino-9-ethylcarbazol (AEC). After washing in dH2O, slides
were counterstained with haematoxylin, dehydrated and mounted.
For determination of apoptosis, 500 cells were evaluated in
representative fields at  400 magnification, and apoptotic cells
were calculated in percent of the total number of counted cells.
Growth of cells in nude mice and procedure of treatment
Evaluation of drug-induced effects in the mouse model was
performed using fast growing, hormone-independent PC3 and
TSU-PR1 cells. Cells were maintained in culture as described and
found to be free of mycoplasma contamination. Cells were
harvested from tissue culture flasks after reaching semiconfluence.
Before injection, cells were washed and resuspended in Dulbecco’s
phosphate-buffered saline (PBS). In all, 10
5 cells were transplanted
on both sides subcutaneously through 0.4 19mm needles in
projection of the scapulae of 7-week-old NMR/ nu/nu male mice
with a mean weight of 30g (Bomholtgard, Denmark). For each
treatment protocol, six mice were used resulting in 12 tumours per
setting. For intraperitoneal application, both sodium butyrate and
tributyrin were dissolved in sterile saline. Treatment was started
24h after implantation of the cells. During the first week, drug
administration was performed on a daily basis for a calculated
final plasma concentration of 10mM. As the mice were estimated
with a 2.4ml blood volume, 24mg of sodium butyrate and 7.9mg
of tributyrin were used (Egorin et al, 1999). From week 2 until the
end of week 4, when the experiment was stopped, application was
carried out every second day. As control, a mock-treated group
with mice growing xenograft tumours and getting normal saline
injections was observed. Tumour size was measured once a week
and tumour volume was calculated according to the formula 1/
2 L W H in millimetres (Tomayko and Reynolds, 1989). The
weight of all mice was measured weekly. All animal experiments
were carried out with ethical committee approval (#631, Regier-
ungspra ¨sidium Tu ¨bingen, Germany) and met the standards as
defined by the UKCCCR guidelines (Workman et al, 1998).
Immunohistochemistry and quantitative assessment of
KI-67 protein expression
Detection of the nuclear protein Ki-67 has been chosen, as it is
preferentially expressed during the active phases of the cell cycle,
but not in the G0-phase. Ki-67 is an accepted means for the
detection of proliferating cells in paraffin-embedded tissue
sections (Cattoretti et al, 1992; Gerdes et al, 1992; Mucci et al,
2000), and its expression has been shown to be associated with
poor outcome in prostate cancer patients (Borre et al, 1998).
Standard avidin–biotin complex immunohistochemistry was used
for staining the animal tumours. Pretreatment was performed by
exposure for 10min in sodium citrate buffer in a microwave oven.
The slides were then incubated sequentially with primary antibody
(1:100 dilution, monoclonal mouse anti-human-Ki-67 antibody,
DAKO Diagnostika, Hamburg, Germany), biotinylated secondary
antibody, avidin–biotin complex and chromogenic substrate 3,30-
diaminobenzidine. Slides were evaluated for adequacy using a
standard bright field microscope. Digital images were acquired and
protein expression was scored as positive or negative using the
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sMDS 5.8 system from Applied Imaging Corporation (Santa Clara,
CA, USA). For objective evaluation, eight representative areas were
defined. In the case of KI-67 protein expression, the system was
optimised for nuclear staining, calculating the percentage of
stained nuclei. Data were transferred to a spreadsheet for
subsequent analysis.
Western blotting
The expression of proteins was determined by Western blot
analysis using specific primary antibodies for p21WAF1, Rb and c-
myc (Oncogene, Cambridge, USA). Briefly, cells were lysed using
RIPA solution (1% nonidet P-40, 0.5% sodium deoxycholate, 0.1%
SDS, 100mgml
 1 phenylmethylsulphonylfluoride, 30mlml
 1 apro-
tinin, 50mgml
 1 leupeptin, in PBS, pH 7.4; chemicals were
purchased from Sigma, Steinheim, Germany) at 41C for 10min.
Lysates were centrifuged and the protein concentration of the
supernatant was determined using the Bradford assay. Laemmli
sample buffer at a ratio of 1:2 was mixed to the sample. Following
electrophoresis, the proteins were transferred onto polyvinylidene
difluoride membranes (Bio-Rad, Munich, Germany). Blocking was
carried out with freshly prepared TBST plus 10% nonfat milk
(20mM Tris-HCl, pH 7.6, 137mM NaCl, 0.1% Tween-20). After
washing, the membrane was incubated for 1h with primary
antibodies diluted in TBST (100–1.500-fold). Appropriate horse-
radish peroxidase-conjugated secondary antibodies (Amersham,
Buckinghamshire, UK) were incubated overnight. For detection,
autoradiography using ECL was performed according to the
manufacturer’s instructions (Amersham, Buckinghamshire, UK).
Statistical analysis
Treatment effect was statistically evaluated using the mean score
result (i.e. percentage of stained nuclei) for each treatment group
(i.e., control, sodium butyrate, tributyrin or various concentra-
tions). To test for significant differences the one-way ANOVA test
was performed. To determine the differences between all pairs,
post hoc analysis using the Scheffe ´ method was applied. Values are
presented in a graphical format using error bars with 95%
confidence intervals (CIs). P-values o0.05 were considered
statistically significant.
RESULTS
Butyrate-induced growth inhibition in vitro
Increasing concentrations of sodium butyrate and tributyrin were
applied onto the cell lines PC3, TSU-Pr1 and LNCaP starting at a
final concentration of 0.5mM up to 5.0mM. Cells were exposed for
72h before absorbance was measured using the XTT assay. The
titration curve for sodium butyrate is given in Figure 1 for the PC3
cells, demonstrating a 50% growth inhibition at about 2.5mM final
concentration. TSU-Pr1 cells were slightly less and the LNCaP cell
line was slightly more sensitive to the treatment. Sodium butyrate
at a dosage of 0.5mM induced already a significant growth
inhibition in all the three cell lines compared to mock-treated cells.
One-way ANOVA analysis revealed a P-value of o0.0001.
Incubation with equimolar concentrations of tributyrin revealed
stronger dose-dependent growth-inhibitory effects (data not
shown). This is in accordance with our previous study, where
further detailed data were presented (Maier et al, 2000).
Quantitative assessment of in vivo induction of apoptosis
in prostate cancer microtumours established on the CAM
Tumours implanted on the CAM were examined quantitatively for
apoptosis following exposure to increasing concentrations of
sodium butyrate or tributyrin (0.1–5mM) by a single i.v. injection.
i.v. Injections of sodium butyrate or tributyrin revealed a strong
apoptotic effect in prostate cancer microtumours over mock-
treated controls as visible in the tissue sections and demonstrated
in Figure 2A–D. Both compounds, sodium butyrate and tributyrin,
led to a dose-dependent increase of apoptotic cells compared to
mock-treated cells. With sodium butyrate, at the maximum
concentration of 5.0mM the corresponding apoptosis rates were
almost similar with 28.775.8, 23.072.7 and 26.075.7% of
apoptotic nuclei in PC3, TSU-PR1 and LNCaP cells, respectively
(Figure 3A). When treated with tributyrin (Figure 3B) PC3 cells
were the most sensitive and LNCaP cells were less sensitive. After
injection of 5.0mM tributyrin, the corresponding rate of apoptotic
nuclei was 3874.5, 27.575.3 and 27.877.5 for PC3, TSU-PR1 and
LNCaP cells, respectively. Compared to a 48h sodium butyrate
exposure, the percentage of apoptotic cells induced by tributyrin
exposure was higher. Interestingly, the dose–response curve of
both compounds showed a substantial rate of apoptotic cells
compared to mock-treated cells at already very low concentrations
of 0.1mM of sodium butyrate or tributyrin.
Inhibition of tumour growth in the mouse model
NMR/ nu/nu male mice (7 weeks old) with an average weight of
30g were used for implantation of human prostate cancer cells
derived from the cell lines PC3 and TSU-Pr1. These cell lines were
chosen for the mouse model as they easily grow without any
additional condition media and form homogeneous tumours. As
graphically demonstrated in Figure 4A, the volume of the PC3
tumours was increasing over time, with the control group having
the largest tumour sizes. After 4 weeks of treatment, the size of the
tumours in the control group was almost double the size compared
to the treatment groups. Between sodium butyrate and tributyrin
treatment, there was no significant difference in tumour size
throughout the observation time. With the less fast growing TSU-
Pr1 cells, the tumours in the control and treatment groups were
smaller. Still similar in vivo effects for the HDACs were observed
applying the identical treatment regimen as for the PC3 cells
(Figure 4B). As a parameter to reflect the general condition of the
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Figure 1 Increasing concentrations of sodium butyrate were applied on
the human prostate cancer cell line PC3 starting at an initial concentration
of 0.5mM up to 5.0mM. Growth inhibition was correlated to absorbance
determined with the XTT assay. The control was set to 100%. The
percentage of viable cells is given as mean values with standard deviation of
repeated experiments.
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sanimals, the weight during the time of the experiments was
documented weekly. Substantial loss of weight did not occur in any
of the treatment groups during the course of the treatment.
Ki-67 immunohistochemistry of mouse tumours
Mouse tumours were removed and tissue sections were stained for
Ki-67 expression in the nuclei. Control tumours, sodium butyrate-
and tributyrin-treated tumours had a mean percentage of stained
nuclei of 74.9 (standard error (s.e.) 2.0, 95% CI 70.6–79.1), 29.1
(s.e. 3.1, CI 22.8–35.5) and 36.7 (s.e. 2.7, CI 31.2–42.2),
respectively. One-way ANOVA analysis revealed a P-value of
o0.0001. To examine specifically the difference between the
different treatment types, a post hoc pairwise comparison was
performed. Control tumours demonstrated a significantly higher
percentage of Ki-67-stained nuclei as compared to sodium
butyrate-treated tumours (Scheffe ´ method, Po0.0001, CI 36.5–
54.9). Sodium butyrate-treated mice showed no significant
different percentage of Ki-67-stained nuclei as compared to
tributyrin-treated tumours (Scheffe ´ P¼0.14; CI –16.9 to 1.8).
The percentage of Ki-67-stained nuclei for the three groups is
graphically demonstrated in Figure 5 for PC3-implanted tumours.
Examples of immunohistochemistry are also given, with Ki-67
staining the nuclei of dark brown cells that are in an active phase
of the cell cycle.
Expression of p21, Rb and c-myc
For Western blot analysis, cells were treated with a final
concentration of 5.0mM sodium butyrate. Protein expression of
the specific targets p21, Rb and c-myc, is demonstrated for PC3
cells in Figure 6. Lysates representing different treatment times,
that is, 12 and 24 and 48h treatment, were run simultaneously on
the same gel, loading equal amounts of protein. The cell cycle
inhibitor p21 was not expressed in untreated PC3 (and TSU-Pr1)
cells, which were both not expressing a wild-type p53. After
exposure to sodium butyrate, p21 expression was induced with a
maximum at 12h post-treatment. P21 possibly could affect c-myc
expression via inhibition of cyclin-CDK-dependent phosphoryla-
tion of Rb. Western blot analysis revealed an Rb-dephosphoryla-
tion after exposure to sodium butyrate in a time-dependent
pattern. Simultaneously, c-myc expression decreased, supporting
the hypothesis of a p214Rb4c-myc-dependent pathway under-
lying the butyrate-induced growth-inhibitory effects.
DISCUSSION
While effective surgical and radiation treatment options can be
offered for clinically localised prostate cancer, advanced prostate
cancer remains incurable. Androgen ablation has been the
standard treatment for metastatic prostate cancer for many years.
Despite an initial response to antiandrogens, disease progresses in
the majority of cases independent of hormonal status. Unfortu-
nately, the surviving cell clones are resistant to standard cytotoxic
chemotherapies as well. Not surprisingly, early clinical trials have
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Figure 2 Prostate cancer microtumours growing on the CAM. (A)I n
the mock-treated control, only very few cells of the tumour, sitting on top
of the CAM, show signs of apoptosis. (B) Strong labelling (red staining) of
tumour cells by immunohistochemistry with an anti-human antibody to
demonstrate the human origin of the evaluated cells (MNF 116 cytoceratin
cocktail (DAKO, Germany). (C) Tributyrin-treated tumours growing on
the CAM. TUNEL assay reveals dark brown staining as a correlate to
apoptotic changes (magnification  20). (D) Higher magnification of (C).
Nuclei-bound staining by TUNEL assay is indicated by white arrows ( 800
magnification).
A Sodium buytrate
0.0 0.1 2.0 5.0
0
10
20
30
40
50
PC3
TSU
LNCaP
Final concentration of
sodium butyrate (mM)
B Tributyrin
0.0 0.1 2.0 5.0
0
10
20
30
40
50
PC3
TSU
LNCaP
Final concentration
of tributyrin (mM)
I
n
 
v
i
v
o
 
a
p
o
p
t
o
s
i
s
 
r
a
t
e
I
n
 
v
i
v
o
 
a
p
o
p
t
o
s
i
s
 
r
a
t
e
Figure 3 (A) Induction of apoptosis in LNCaP, PC3 and TSU-Pr1
human prostate cancer cells by increasing concentrations of sodium
butyrate. The final in vivo concentration of i.v.-applied sodium butyrate
varied from 0.1 to 5.0mM. Normal saline injection served as a negative
control. Apoptotic cells were assessed using the TUNEL assay. (B)
Induction of apoptosis in the three cell lines LNCaP, PC3 and TSU-Pr1 with
increasing concentrations of tributyrin.
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sdemonstrated only a very limited benefit in patients with advanced
prostate cancer disease (Yagoda and Petrylak, 1993). The
chemotherapy regimen was partly unsuccessful as patients had
large symptomatic tumour burden, and due to their advanced age
often presented with confounding comorbidities. The patients with
advanced disease nowadays present a lot earlier and due to the
merit of up-to-date medicine mostly with well-controlled comor-
bidities. These clinical aspects and increasing knowledge about
biomolecular conditions of prostate cancer based on new
technologies (Dhanasekaran et al, 2001) facilitate the identification
of new chemopreventive and chemotherapeutic options for the
treatment of prostate cancer. Novel agents often influence path-
ways that are underlying prostate cancer growth and survival. The
rationale for this type of approach is the hope of increased
antitumour activity with less toxicity, as those pathways are
targeted that are critical for malignant but not for normal cell
differentiation, proliferation and survival. One of the promising
groups of drugs is the HDACs.
In our previous study, we have shown several in vitro effects
caused by treatment of PC3, TSU-Pr1 and LNCaP cells with sodium
butyrate or tributyrin (Maier et al, 2000). These effects included
cell swelling, nuclear disruption, cell cycle arrest in the G1 phase
and dose-dependent induction of apoptosis. In the XTT assay
analysis in this study, the LNCaP cell line was most sensitive
compared to PC3 and TSU-Pr1 cells. This could possibly be
explained by the fact that LNCaP cells are known to be a cell line
expressing prostatic markers and being hormone sensitive,
whereas PC3 and TSU-Pr1 cells are less differentiated (Kaighn
et al, 1979; Horoszewicz et al, 1983; Webber et al, 1996). PC3 and
TSU-Pr1 cells carry molecular alterations such as a mutated p53
and the origin of TSU-Pr1 cells is discussed controversially (Iizumi
et al, 1987; van-Bokhoven et al, 2001). On the chicken egg
membrane, PC3 tumours seemed to be more sensitive especially
when treated with tributyrin. For all cell lines it could be noted, in
accordance with the reported in vitro observations, that sensitivity
was higher when treated with tributyrin. The parameter chosen for
quantification of the treatment effect was the number of apoptotic
cells. This experiment demonstrates that the used butyrates show
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Figure 4 (A) PC3 cells were transplanted in male nude mice. Tumour
volume was measured once weekly and is given as an average of 12
tumours. The mice were treated with either normal saline, sodium butyrate
or tributyrin by i.p. injections with an estimated plasma concentration of
10mM for the compounds. (B) Tumour volume after implantation of TSU-
Pr1 prostate cancer cells in male nude mice. Same control and treatment
groups as given in (A) for PC-3 cells.
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Figure 5 Immunohistochemistry was performed for protein expression
of Ki-67. Control mouse tumours, sodium butyrate- and tributyrin-treated
mouse tumours were stained with anti-human Ki-67 monoclonal antibody.
Ki-67-positive cells are stained dark brown. Nuclear staining was evaluated
with a computerised system. Mean percentages of positive nuclei are
graphically given with 95% CI. Examples of tissue sections stained for Ki-67
for the control group, the sodium butyrate- and tributyrin-treated group
are given.
Figure 6 Western blot analysis using specific antibodies for detection of
p21, Rb and c-myc expression. The presented blots represent expression
of the targets of sodium butyrate-treated PC3 human prostate cancer cells.
Expression was evaluated at several time points after treatment (internal
loading control not shown). P21 expression was induced by sodium
butyrate with a maximum at 12h post-treatment. Rb expression shifted to
the hypophosphorylated form in a time-dependent pattern. Simultaneously,
c-myc expression decreased. Molecular weights are given in kDa.
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sin vivo efficiency via the induction of apoptosis. The verification of
cells of human origin was carried out by immunohistochemistry
using a cytokeratin antibody cocktail. Based on the promising
results of this in vivo model, mouse experiments were conducted
for verification. In the mouse experiments we aimed for a plasma
concentration of 10mM for both drugs according to published
pharmacological calculations for butyrates (Egorin et al, 1999).
Although it could be demonstrated that relevant plasma concen-
trations can be achieved by oral administration (Egorin et al, 1999)
in this study, drug application was performed by injection. Drug
application by mixing the substances with the food did not prove
to be effective as the pellets were partly disregarded by the animals,
resulting in considerable variations of plasma levels. In compar-
ison to the very sensitive CAM assay, in which a similar treatment
effect as observed in the cell culture experiments was achieved with
a single dose, a much higher total dosage was needed in the mouse
model. This is most likely due to delivery and metabolism (Miller
et al, 1987). During the course of 4 weeks, more resistant cell
clones most probably do not emerge. The tumour size was
significantly less increasing in the treated animals with no
significant difference between sodium butyrate or tributyrin
applied with equal final plasma concentration. None of the mice
died due to acute toxic treatment effects and none of the animals
showed major changes in the weight as a parameter for good drug
tolerance. The tumour sizes correlate well with the percentage of
Ki-67-stained nuclei as observed by immunohistochemistry and
computerised objective evaluation. In this study, the Ki-67-positive
cells were significantly less in the treated group compared to the
control group of untreated mice. Increased differentiation induced
by butyrates has been shown earlier in in vitro experiments using
the LNCaP cell lines (Carducci et al, 1996).
The given immunoblot results suggest that the mechanism for a
treatment effect by butyrates is independent of a wild-type p-53
status (Carducci et al, 1996). Overexpression of p21 has been
shown to activate Rb (Agarwal et al, 1998; Keegan et al, 1998). Rb
is known to be functionally active in an underphosphorylated
conformation and is inactivated during the late G1 phase by cyclin-
dependent phosphorylation, allowing the cells to proceed from G1
to S phase (Zhao et al, 1997). The given results suggest that an
intact p21, Rb and c-myc may have to be present for treatment
effect. A similar observation has been made for a novel HDAC
inhibitor FK228 (Sasakawa et al, 2003). Still, the given data
obviously look only at a very small portion of possibly involved
pathways and thus have to be considered as preliminary. It cannot
be ruled out that the observed changes could be a parallel issue as
for example growth inhibition, induced by sodium butyrate, has
been described in a cell line that has abrogated Rb function
(Rashid et al, 2001). There might be other and potentially even
more important structures such as cyclin A and D, p27 and protein
kinase C, which are involved in the process of butyrate-induced
growth inhibition (Chen et al, 2003; Kim et al, 2003; Siddiqui et al,
2003). Nevertheless, exploring the activation of p-21, including the
role of Sp1 transcription factor, is a very promising approach
(Wang et al, 2000; Rashid et al, 2001; Margueron et al, 2003), as
this gene appears to be rarely mutated in common human
malignancies in contrast to p53 (Terao et al, 2001). A similar
pattern of mechanism has been described for several cell lines
including prostate cancer cell lines for the effect of phorbol ester
(Blagosklonny et al, 1997). This observation possibly suggests that
a combination of phorbol ester and butyrates may have an additive
effect on tumour cells (McBain et al, 1996; Rahmani et al, 2002).
In contrast to the majority of solid tumours, prostate cancer is a
very heterogeneous tumour, which is obvious for example in the
various Gleason patterns represented in one gland (Gleason, 1966).
New technologies such as laser microdissection help to gain an
insight into the underlying patho-morphologies of distinct tumour
cells (Rubin, 2002). This may aid in understanding the complexity
of intervening pathways of prostate cancer growth. From this
understanding, it is likely that monotherapy might not be
sufficient for treatment but rather a combination of drugs
targeting various mechanisms. Based on the presented in vivo
results, butyrates are very promising agents in prostate cancer
control independent of hormone sensitivity. The anticancer effects
might be supported by a combination with other drugs and a
combined treatment approach may offer the chance to a reduced
dosage with less side effects (Newmark and Young, 1995; Conley
et al, 1998; Halicka et al, 2000; Banwell et al, 2003).
In this study, we have demonstrated a substantial in vivo
treatment effect, which can be induced by the application of
sodium butyrate or the orally applicable tributyrin in human
prostate cancer. These two HDACs have shown a strong cell
growth-inhibitory and proapoptotic activity. These effects seem to
be independent of p53 status and a pathway including p21, Rb and
c-myc is possibly involved in these effects. The given in vivo results
may provide the rationale to apply these HDACs in well-controlled
clinical trials as ‘gene-regulating chemoprevention’ in patients
being at high risk of recurrence after specific therapy or as ‘gene-
regulating chemotherapy’ in a combination regimen for patients
with locally or distant advanced prostate cancer.
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